Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Fiche publication
Date publication
janvier 2010
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry
Tous les auteurs :
Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, Conroy T, Dominguez S, Faroux R, Florentin V, Douillard JY
Lien Pubmed
Résumé
OBJECTIVE: In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy to the infusional FOLFOX-6 regimen in first-line treatment of metastatic colorectal cancer (mCRC). The objective of this additional analysis was to compare the cost of XELOX and FOLFOX-6. METHODS: This cost-minimisation study took into account costs related to drug acquisition, hospital care for chemotherapy administration and for serious adverse event management. Hospital care costs were based on French 'diagnosis-related group' tariffs. Drug acquisition costs were drawn from French official sources. Analysis was performed from the French health insurance perspective. RESULTS: Baseline characteristics of the 282 patients included (143 XELOX, 139 FOLFOX-6) were well balanced. Patients reported less and shorter hospitalisations (day and overnight hospital care) with XELOX: 6.4 +/- 2.2 hospitalisations versus 9.7 +/- 3.1 (p < 0.001); 11.4 +/- 10.6 days versus 17.7 +/- 11.8 (p < 0.001). Mean disease management cost per patient was significantly lower with XELOX (EUR 12,918 +/- 5,075 vs. EUR 17,229 +/- 8,665, p < 0.001). CONCLUSION: In the perspective of our analysis, taking into account hospitalisation and drug acquisition costs, the treatment of mCRC patients with XELOX in comparison to FOLFOX-6 significantly decreased the costs, as well as the mean overall hospitalisation length of stay.
Référence
Oncology. 2010;79(3-4):174-80